Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by Nathalie Bonnefoy
Group name EquipeNB
Item Type Journal Article
Title Advanced penile cancer with iliac lymph node involvement treated with radiation and concurrent gemcitabine
Creator Lapierre et al.
Author A. Lapierre
Author O. Riou
Author A. Fléchon
Author N. Mottet
Author D. Azria
Abstract Penile cancer is a rare entity with only 2000 new cases a year in the United States. Even though early stage penile cancer has an excellent prognosis, patients with positive pelvic lymph nodes have an overall 5-year survival rate under 10%. There is no consensus for the management of pelvic node-positive patients, although most guidelines are in favour of pelvic lymph node dissection for patients with two or more positive nodes, followed by adjuvant chemotherapy. We describe here the case of a patient with numerous metastatic lymph nodes at diagnosis, treated with chemoradiation (66Gy with concurrent gemcitabine) after failure of first-line chemotherapy and still alive and disease-free 7 years after diagnosis.
Publication Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique
Volume 21
Issue 2
Pages 134-137
Date Apr 2017
Journal Abbr Cancer Radiother
Language eng
DOI 10.1016/j.canrad.2016.10.003
ISSN 1769-6658
Library Catalog PubMed
Extra PMID: 28411892
Tags Adult, Antimetabolites, Antineoplastic, Chemoradiotherapy, Chimioradiothérapie, clinic, Combined Modality Therapy, Deoxycytidine, Humans, Lymphatic Metastasis, Male, Pelvis, Penile Neoplasms, Radiothérapie, Radiotherapy, Tumeurs du pénis
Date Added 2019/05/28 - 22:04:41
Date Modified 2019/05/28 - 22:25:31
Notes and Attachments PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés